Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Immune tolerance deal underway
November 2017
SHARING OPTIONS:

HAMBURG, Germany—A new multiyear agreement was established in the third quarter of the year between Topas Therapeutics GmbH and Eli Lilly and Co., under which the companies will combine their strengths in antigen-specific tolerance induction, with an initial focus on external antigens believed to induce inflammation and/or autoimmune disease. Topas will conduct preclinical proof-of-principle studies in collaboration with Lilly to generate drug candidates, and Lilly will have an option to in-license and further develop all candidates resulting from this deal. Lilly will provide R&D funding for this work, and Topas will share in the future success of any compounds Lilly chooses to in-license.
 
Dr. Thomas F. Bumol, Lilly’s senior vice president of biotechnology and immunology research, noted that “Topas has a very novel approach to immune tolerance induction, which we would like to see successfully applied to certain disease-relevant antigens. We look forward to working together with Topas on their unique platform.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.